Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The ONKOTEV score predicts the risk of venous thromboembolism in cancer patients.
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.
At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.
Fibromyalgia in 2025: Year in Review
Rheumatoid Arthritis in 2025: Year in Review
Asthma in 2025: Year in Review
C3 Glomerulopathy in 2025: Year in Review
1.
A better option for mild to moderate depression?
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
Stevia leaf extract has potential as anticancer treatment, researchers find
4.
A US health panel advises starting mammograms at age 40 rather than 50.
5.
Some triple negative breast cancers might be avoided by longer breastfeeding
1.
Diagnosis and Treatment of Follicular Thyroid Cancer: A Comprehensive Guide
2.
Exploring the Normal Range of Monocytes: A Comprehensive Guide
3.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
4.
Hemoglobin C: Understanding its Role in Sickle Cell Disease
5.
Neutrophil Profiling and AI Rewrites Cancer Diagnosis
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
3.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge